enGene Holdings Inc. Common Stock Asset Resilience Ratio
enGene Holdings Inc. Common Stock asset resilience ratio. enGene Holdings Inc. Common Stock (ENGN) has an Asset Resilience Ratio of 78.14% as of July 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can enGene Holdings Inc. Common Stock fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of enGene Holdings Inc. Common Stock (2023–2025)
Asset resilience ratio of enGene Holdings Inc. Common Stock from 2023 to 2025. This chart shows how enGene Holdings Inc. Common Stock's Asset Resilience Ratio has changed over time. Read ENGN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down enGene Holdings Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is enGene Holdings Inc. Common Stock's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $225.29 Million | 78.14% |
| Total Liquid Assets | $225.29 Million | 78.14% |
Asset Resilience Insights
- Very High Liquidity: enGene Holdings Inc. Common Stock maintains exceptional liquid asset reserves at 78.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
enGene Holdings Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare enGene Holdings Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
enGene Holdings Inc. Common Stock Asset Resilience Ratio by Year (2023–2025)
enGene Holdings Inc. Common Stock asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for enGene Holdings Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-10-31 | 64.87% | $143.66 Million | $221.47 Million | +43.85pp |
| 2024-10-31 | 21.02% | $65.40 Million | $311.17 Million | +20.93pp |
| 2023-10-31 | 0.09% | $76.00K | $86.96 Million | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more